Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Qlik Technologies Inc in connection with its listing on Nasdaq
Mandate

Vinge advises Qlik Technologies Inc in connection with its listing on Nasdaq

August 13, 2010

Vinge has advised Qlik Technologies Inc in connection with its admission to listing on Nasdaq Global Market. The total share value on listing amounts to approximately
USD 750,000,000.

Qlik Technologies Inc was originally established in Lund in 1993. The company has developed and licenses the increasingly popular business intelligence software, “QlikView”. Qlik has 14,000 customers and 570,000 users in more than 100 countries.

Vinge’s team consisted of responsible partner Henrik Borna together with partners Sofia Olsson and Erik Sjöman, counsel Maria Schultzberg and associates Magnus Bigner and Fredrik Christiansson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024